Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.48 |
| ▸ | PARP11 | Q9NR21 | 6/20 | 0.48 |
| ▸ | PARP1 | P09874 | 4/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8658609 | 0.80 | CA12 (0.45) | RYR2ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL12849393 | 0.78 | ALDH1A1 (0.46) | RYR2ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL9635035 | 0.77 | ALDH1A1 (0.53) | RYR2ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL1238947 | 0.75 | RYR2 (0.61) | RYR2ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL1238521 | 0.75 | PRKD1 (0.50) | RYR2ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL9635151 | 0.75 | PARP10 (0.50) | RYR2ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL26942243 | 0.75 | PARP10 (0.54) | RYR2ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL30657972 | 0.75 | PARP10 (0.54) | RYR2ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL26653947 | 0.75 | PARP10 (0.54) | RYR2ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL14691900 | 0.75 | PARP10 (0.50) | RYR2ALDH1A1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022057142-A1 | STEROID SYNTHETASE INHIBITORS AND THERAPEUTIC USE THEREOF | 广州中医药大学(广州中医药研究院) | 2022-03-24 | — | — | WO | claimed |
| EP-4745139-A1 | COMPOUND FOR TREATING AND PREVENTING RESPIRATORY SYNCYTIAL VIRUS INFECTION DISEASES | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-119285628-A | Compounds for the treatment and prophylaxis of respiratory syncytial virus infection diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118852149-A | Compound for treating or preventing RSV virus diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYCARMA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYCARMA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| CN-110407769-B | 3, 4-dihydro-benzo [ f ] [1,4] thiazepine-5 (2H) -one compounds and pharmaceutical use thereof | 复旦大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
| US-20070098631-A2 | DIAGNOSTIC COMPOUNDS COMPRISING A SCAFFOLD COUPLED TO A SIGNAL ENTITY FOR MEDICAL IMAGING DIAGNOSTIC | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
| US-20070098631-A2 | DIAGNOSTIC COMPOUNDS COMPRISING A SCAFFOLD COUPLED TO A SIGNAL ENTITY FOR MEDICAL IMAGING DIAGNOSTIC | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
| US-7008938-B2 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | NOKIA CORPORATION (FI) | 2006-03-07 | — | — | US | disclosed |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| US-6809092-B2 | 1,3,4,5-TETRAHYDRO-2H-2-BENZAZEPIN-2-YL DERIVATIVES; CYSTEINE PROTEASE INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | disclosed |
| EP-1254898-A1 | BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-0368063-B1 | PROCESS FOR THE CHLORINATION IN THE NUCLEUS OF AROMATIC HYDROCARBONS | BAYER AG (DE) | 1992-06-10 | — | — | EP | disclosed |
| US-4990707-A | Process for the ring chlorination of aromatic hydrocarbons | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYR2, RYR1, ATP2A1 | RYR2 1/4885ALDH1A1 2677/4885MEN1 4283/4885 |
| US-20070098631-A2 | DIAGNOSTIC COMPOUNDS COMPRISING A SCAFFOLD COUPLED TO A SIGNAL ENTITY FOR MEDICAL IMAGING DIAGNOSTIC | HTR3D, BRD4, CNR1 | RYR2 57/4885ALDH1A1 639/4885MEN1 1323/4885 |
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | KCNB2, KCNJ2, KCNJ5 | RYR2 275/4885ALDH1A1 886/4885MEN1 2138/4885 |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | BACH1, BACE1, CMA1 | RYR2 500/4885ALDH1A1 1884/4885MEN1 2086/4885 |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | BACE1, BACE2, CBS | RYR2 353/4885ALDH1A1 3625/4885MEN1 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.